U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07174687) titled 'SGLT2 Inhibitors in Geographic Atrophy' on Sept. 05.
Brief Summary: AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Retinal Degeneration
Retinal Diseases
Eye Diseases
Geographic Atrophy
Pathological Conditions, Anat...